Momeny, Majid <br/><br/>
The ERBB receptor inhibitor dacomitinib suppresses proliferation and invasion of pancreatic ductal adenocarcinoma cells.  [electronic resource] 

 -  Cellular oncology (Dordrecht, Netherlands)  Aug 2019 
 - 491-504 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>2211-3436 
<br/><br/><label>Standard No.: </label>10.1007/s13402-019-00448-w  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Apoptosis--drug effects<br/>Carcinoma, Pancreatic Ductal--drug therapy<br/>Cell Line, Tumor<br/>Cell Movement--drug effects<br/>Cell Proliferation--drug effects<br/>Cell Survival--drug effects<br/>ErbB Receptors--antagonists & inhibitors<br/>Humans<br/>Models, Biological<br/>Neoplasm Invasiveness<br/>Pancreatic Neoplasms--drug therapy<br/>Quinazolinones--pharmacology<br/>Radiation Tolerance